Robert M. Thomas, Jr. of Thomas and Associates, Boston, MA -- Bob Thomas: Whistleblower, qui tam law, false claims act, fraud, internal investigations and more.

Set the Record Straight
We are trial lawyers focusing on fraud cases: qui tam whistle-blower representation, internal investigations, white collar litigation, and criminal defense. Thomas & Associates has represented clients in False Claims Act cases that have led to the recovery of over $ 3 billion for U.S. taxpayers, and millions to our clients. We know how to set the record straight. Learn more»

ROBERT M. THOMAS, JR.
AND ASSOCIATES

· Firm Overview
· Practice Areas
· Contact Us



		· Whistleblower Representation · False Claims Act and · Qui Tam Litigation
		The False Claims Act is the primary tool to help expose fraud in government programs from healthcare to homeland defense, from public utilities to public works, while protecting those who step forward. Access our Whistleblower Info Center
		*learn more »*



		Internal Investigations of Fraud & Corruption
		Thomas & Associates has a proven track record conducting internal investigations on behalf of labor unions, banks, and companies. Bob Thomas serves as special prosecutor of labor corruption cases across the country, involving primarily anti-racketeering (RICO) cases.
		*learn more »*



		· Civil and Criminal Litigation · Grand Jury Investigations · White Collar Criminal Defense
		Extensive courtroom experience is the foundation for Thomas & Associates success in criminal law and civil litigation. We represent individuals in criminal grand jury investigations and complex white-collar fraud matters.
		*learn more »*

NEWS AND EVENTS

AMGEN ARANESP KICKBACK NEWS
Boston attorneys Suzanne E. Durrell, Robert M. Thomas, Jr., and Rory Delaney, and Los Angeles attorneys Charles F. Kester and Lawrence M. Isenberg of the law firm Kester & Isenberg, announced today the filing of an amended complaint against biotechnology company Amgen Inc. and others, in a case pending before United District Court Judge William G. Young in Boston. The amended complaint, filed pursuant to federal and state False Claims Acts by Relator Kassie Westmoreland, a former Amgen employee, is filed the same day as a consolidated complaint in intervention brought by fifteen state Attorney General offices. These state plaintiffs recently filed notices of intervention in Ms. Westmoreland's lawsuit.
Related Press Release | (PDF)
Amended Complaint (PDF) | Multistate Amgen Complaint (PDF)

Amgen Is Accused of Illegal Kickbacks
New York Times

View latest news stories and blog analysis on this topic as aggregated by Google News

$2.3 BILLION PFIZER SETTLEMENT NEWS

Pfizer Inc. will pay approximately $2.3 billion dollars to settle claims it misbranded one of its pain killer drugs, promoted the off label use of numerous drugs, and paid kickbacks to doctors to induce or reward the prescription of Pfizer drugs. Boston attorneys Suzanne E. Durrell, Robert M. Thomas, Jr. and Rory Delaney represent one of the whistleblowers, Blair Collins, who brought kickback allegations regarding the drugs Lipitor, Norvasc, Viagra, Zithromax, and Zyrtec, and whose information helped form the basis for today's settlement.
Read the Pfizer Settlement Press Release | (PDF)

Official DOJ Pfizer Announcement

RELATED STORIES
VIDEO: Drug maker Pfizer to pay record $2.3 billion penalty over promotions
(NECN: Washington) - Pfizer Inc., the world's largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription drug promotions. The...

Pfizer To Pay $2.3B To Settle Case On Drug Marketing - DOJ
Wall Street Journal - WASHINGTON (Dow Jones)--Pfizer Inc. (PFE) has agreed to pay $2.3 billion to settle charges that it illegally ...

Pfizer Pays $2.3 Billion to Settle Marketing Case
New York Times

Pfizer settles drug-promotion case for $2.3 billion
MarketWatch

Pfizer, Subsidiary to Pay $2.3B in Health-Care Fraud Case
Washington Post

Pfizer to pay record $2.3B penalty over promotions
Boston Globe

View latest news stories and blog analysis on this topic as aggregated by Google News

FOREST LABORATORIES FRAUD NEWS

Read the United States' DOJ Announcement. (PDF)
A Complaint was unsealed today in U.S. District Court in Massachusetts against a New York pharmaceutical company for alleged False Claims Act violations arising from the company’s marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying kickbacks to induce physicians to prescribe the drugs.
Complete Press Release. (PDF)

Read the United States' Complaint. (PDF)

RELATED STORIES
Forest says 11 states will join fraud lawsuit
Forest Laboratories Inc. said Thursday 11 states and the District of Columbia are planning to become plaintiffs in a lawsuit that alleges the company committed fraud against federal health plans.
Complete AP story on FORBES site.

Drug Maker Is Accused of Fraud
The Justice Department charged the drug maker Forest Laboratories on Wednesday with defrauding the government of millions of dollars by illegally marketing the popular antidepressants Celexa and Lexapro for unapproved uses in children and teenagers.
Complete story on The New York Times site.

View latest news stories and blog analysis on this topic as aggregated by Google News

BIG DIG FRAUD NEWS

Big Dig Whistleblower Dan Johnston Pleased with 10-9 Concrete Fraud Settlement—Encourages Others to Come Forward
Read the press release. (Or, download PDF)
                                                                                          (PHOTO: JOSH REYNOLDS FOR THE BOSTON GLOBE, HOSTED ON BOSTON.COM)
RELATED STORIES
Big Dig payment for fraud at $50m

Big Dig firm seen in $42m settlement--Supplier linked to faulty concrete
Complete story on Boston Globe site. |  Related Globe story  |  Newswire Coverage

JANUARY 2008 NEWS

DOJ & Mass. AG: Big Dig Management Consultant and Designers to Pay $450 Million
Read the official announcement.

Boston Globe Editorial: Shoddy work, big settlement
Read the article.

» Read all stories on this topic (Generates customized Google news search results in a new window.)